

Special Issue

Acute and Chronic Viral Hepatitis

Message from the Guest Editors

Viral hepatitis remains one of the biggest public health problems worldwide in need of an urgent response. There are approximately 325 million people globally living with a hepatitis infection. Viral hepatitis caused 1.34 million deaths in 2015, a number comparable to deaths caused by tuberculosis and higher than those caused by HIV. The WHO's global hepatitis strategy, endorsed by all WHO Member States, aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030. For World Hepatitis Day 2021, the WHO focused on the theme "Hepatitis Can't Wait" to highlight the urgency of hepatitis elimination with a view to achieving the 2030 elimination targets. In this Special Issue titled "Acute and Chronic Viral Hepatitis", we welcome both basic and clinical studies of all aspects regarding acute and chronic viral hepatitis.

Guest Editors

Dr. Lin Wang

Department of Microbiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

Prof. Dr. Fengmin Lu

Department of Microbiology and Infectious Disease Center, Peking University Health Science Center, Beijing 100191, China

Deadline for manuscript submissions

closed (30 September 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/113446

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://viruses.mdpi.com)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).